Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, Galimberti M, Giardini C, Gaziev D, Polchi P
Divisione di Ematologia e Centro Trapianto Midollo Osseo di Muraglia, and Azienda Ospedale di Pesaro, Italy.
Blood. 1997 Aug 1;90(3):994-8.
In thalassemia after successful bone marrow transplantation (BMT), iron overload remains an important cause of morbidity. After BMT, patients have normal erythropoiesis capable of producing a hyperplastic response to phlebotomy so that this procedure can be contemplated as a method of mobilizing iron from overloaded tissues. A phlebotomy program (6 mL/kg blood withdrawal at 14-day intervals) was proposed to 48 patients with prolonged follow-up (range, 2 to 7 years) after BMT. Seven patients were not submitted to the program (five because of refusal and two because of reversible side effects). The remaining 41 patients (mean age, 16 +/- 2.9 years) were treated for a mean period of 35 +/- 18 months. All were evaluated before and after 3 +/- 0.6 years of follow-up. Values are expressed as mean +/- standard deviation (SD) or as median with a range (25 to 75 percentile). Serum ferritin decreased from 2,587 (2,129 to 4,817) to 417 (210 to 982) microg/L (P < .0001), total transferrin increased from 2.34 +/- 0.37 to 2.7 +/- 0.58 g/L (P = .0001), transferrin saturation decreased from 90% +/- 14% to 50% +/- 29% (P < .0001). Liver iron concentration evaluated on liver biopsy specimens decreased from 20.8 (15.5 to 28.1) to 4.2 (1.6 to 14.6) mg/g dry weight (P < .0001). Aspartate transaminase decreased from 2.7 +/- 2 to 1.1 +/- 0.6 (P < .0001) and alanine transaminase from 5.2 +/- 3.4 to 1.7 +/- 1.2 (P < .0001) times the upper level of normality. The Knodell score for liver histological activity decreased from 6.9 +/- 3 to 4.9 +/- 2.8 (P < .0001). These data indicate that phlebotomy is safe, efficient, and widely applicable to ex-thalassemics after BMT.
在成功进行骨髓移植(BMT)后的地中海贫血患者中,铁过载仍然是发病的重要原因。BMT后,患者的红细胞生成正常,能够对放血产生增生反应,因此可以考虑将放血作为一种从过载组织中动员铁的方法。我们对48例BMT后随访时间延长(范围为2至7年)的患者提出了一个放血方案(每14天抽取6 mL/kg血液)。7例患者未接受该方案(5例因拒绝,2例因可逆性副作用)。其余41例患者(平均年龄16±2.9岁)接受治疗的平均时间为35±18个月。所有患者在随访3±0.6年后进行了评估。数值以平均值±标准差(SD)表示,或以中位数及范围(第25至75百分位数)表示。血清铁蛋白从2587(2129至4817)降至417(210至982)μg/L(P <.0001),总转铁蛋白从2.34±0.37增至2.7±0.58 g/L(P =.0001),转铁蛋白饱和度从90%±14%降至50%±29%(P <.0001)。肝活检标本评估的肝脏铁浓度从20.8(15.5至28.1)降至4.2(1.6至14.6)mg/g干重(P <.0001)。天冬氨酸转氨酶从2.7±2降至1.1±0.6(P <.0001),丙氨酸转氨酶从5.2±3.4降至1.7±1.2(P <.0001)倍正常上限。肝脏组织学活性的Knodell评分从6.9±3降至4.9±2.8(P <.0001)。这些数据表明,放血对BMT后的地中海贫血患者是安全、有效的,且广泛适用。